Scopus
🔓 Açık Erişim YÖKSİS DOI Eşleşti
SJR Q1
Management of ocular allergy
Allergy European Journal of Allergy and Clinical Immunology · Eylül 2019
YÖKSİS Kayıtları
YÖKSİS Kayıtları — ISSN Eşleşmesi
ILC3 deficiency and generalized ILC abnormalities in DOCK8‐deficient patients
2019 ISSN: 0105-4538 SCI
Prof. Dr. HASİBE ARTAÇ →
Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU
2019 ISSN: 0105-4538 SCI
Doç. Dr. KEMAL EROL →
Management of patients with chronic rhinosinusitis during the COVID\u201019 pandemic\u2014An EAACI position paper
2021 ISSN: 0105-4538 SSCI Q1
Prof. Dr. BANU BOZKURT →
Development and preclinical evaluation of virus\u2010like particle vaccine against COVID\u201019 infection
2021 ISSN: 0105-4538 SCI-Expanded
Prof. Dr. OSMAN ERGANİŞ →
Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses
2022 ISSN: 0105-4538 SCI
Prof. Dr. HASİBE ARTAÇ →
Makale Bilgileri
ISSN01054538
Yayın TarihiEylül 2019
Cilt / Sayfa74 · 1611-1630
Scopus ID2-s2.0-85068172537
Erişim🔓 Açık Erişim
Özet
The treatment and management of ocular allergy (OA) remain a major concern for different specialties, including allergists, ophthalmologists, primary care physicians, rhinologists, pediatricians, dermatologists, clinical immunologists, and pharmacists. We performed a systematic review of all relevant publications in MEDLINE, Scopus, and Web Science including systematic reviews and meta-analysis. Publications were considered relevant if they addressed treatments, or management strategies of OA. A further wider systematic literature search was performed if no evidence or good quality evidence was found. There are effective drugs for the treatment of OA; however, there is a lack an optimal treatment for the perennial and severe forms. Topical antihistamines, mast cell stabilizers, or double-action drugs are the first choice of treatment. All of them are effective in reducing signs and symptoms of OA. The safety and optimal dosing regimen of the most effective topical anti-inflammatory drugs, corticosteroids, are still a major concern. Topical calcineurin inhibitors may be used in steroid-dependent/resistant cases of severe allergic keratoconjunctivitis. Allergen-specific immunotherapy may be considered in cases of failure of first-line treatments or to modify the natural course of OA disease. Based on the current wealth of publications and on the collective experience, recommendations on management of OA have been proposed.
Yazarlar (13)
1
Andrea Leonardi
ORCID: 0000-0002-7246-8580
2
Diana Silva
3
Daniel Perez Formigo
4
Banu Bozkurt
ORCID: 0000-0002-9847-3521
5
Vibha Sharma
6
Pia Allegri
7
Carmen Rondon
ORCID: 0000-0003-0976-3402
8
Virginia Calder
9
Dermot Ryan
ORCID: 0000-0002-4115-7376
10
Marek L. Kowalski
ORCID: 0000-0002-8442-2774
11
Luis Delgado
12
Serge Doan
13
Jean L. Fauquert
Anahtar Kelimeler
allergic conjunctivitis
management
ocular allergy
systematic review
treatment
Kurumlar
Centre Hospitalier Universitaire de Clermont-Ferrand
Clermont-Ferrand France
Edinburgh Medical School
Edinburgh United Kingdom
Faculdade de Medicina da Universidade do Porto (FMUP)
Porto Portugal
Fondation Adolphe de Rothschild
Paris France
Hospital Regional Universitario Carlos Haya
Malaga Spain
Hospital Universitario de Torrejón
Madrid Spain
Medical University of Lodz
Lodz Poland
Rapallo Hospital
Genoa Italy
Royal Manchester Children's Hospital
Manchester United Kingdom
Selçuk Üniversitesi
Selçuklu Turkey
UCL Institute of Ophthalmology
London United Kingdom
Universidad Francisco de Vitoria
Pozuelo de Alarcon Spain
Università degli Studi di Padova
Padua Italy
Scimago Dergi (ISSN Eşleşmesi)
Allergy: European Journal of Allergy and Clinical Immunology
Q1
SJR Skoru3,851
H-Index226
YayıncıWiley-Blackwell Publishing Ltd
ÜlkeUnited Kingdom
Immunology (Q1)
Immunology and Allergy (Q1)
Metrikler
96
Atıf
13
Yazar
5
Anahtar Kelime